Table 2 Prevalence of obesity/overweight, abdominal obesity, dysfunctional adipose tissue, metabolic risk factors, and subclinical cardiovascular disease among Jackson Heart Study participants with stage 2 and 3 Cardiovascular-Kidney-Metabolic (CKM) syndrome at baseline.
| Â | Cardiovascular-Kidney-Metabolic syndrome stage | |
|---|---|---|
|  | Stage 2 (N = 1464) | Stage 3 (N = 225) |
Metabolic Risk Factors, n (%) | ||
Overweight/obesity, abdominal obesity, dysfunctional adipose tissue | ||
Obesity | 1399 (95.5%) | 210 (93.3%) |
Abdominal obesity | 1010 (68.9%) | 180 (80.0%) |
Dysfunctional adipose tissue | 704 (48.1%) | 114 (50.7%) |
Obesity, abdominal obesity, or dysfunctional adipose tissue | 1464 (100%) | 225 (100%) |
Metabolic risk factors | ||
Hypertension, % | 1166 (79.6%) | 214 (95.1%) |
Diabetes, % | 232 (15.8%) | 99 (44.0%) |
Hypertriglyceridemia, % | 461 (31.4%) | 72 (32.0%) |
Moderate – High risk CKD | 575 (39.2%) | 131 (58.2%) |
Metabolic syndrome | 623 (42.5%) | 131 (58.2%) |
Number of metabolic risk factors, n (%) | ||
0 | 0 (0%) | 0 (0%) |
1 | 544 (37.1%) | 40 (17.7%) |
2 | 439 (29.9%) | 45 (20.0%) |
3 | 308 (21.0%) | 62 (27.5%) |
4 | 154 (10.5%) | 59 (26.2%) |
5 | 19 (1.3%) | 19 (8.4%) |
Subclinical CVD, n (%) | ||
Left ventricular hypertrophy | 0 (0%) | 117 (52.0%) |
High risk CVD (PREVENT equation 10-year total CVD risk ≥ 20%) | 0 (0%) | 132 (58.6%) |
